Citi raised the firm’s price target on Bausch + Lomb (BLCO) to $15 from $13 and keeps a Neutral rating on the shares. The firm adjusted targets in medical technology as part of a Q2 earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Mixed Product Performance and Market Challenges Justify Hold Rating for Bausch + Lomb
- Bausch + Lomb to Announce Q2 2025 Results and Host Investor Day
- Bausch + Lomb Secures €675 Million Notes Offering and Refinances Credit Agreement
- Bausch + Lomb Expands Note Offering to €675 Million
- Bausch + Lomb Launches €600 Million Notes Offering